Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus neutralizing antibody
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intranasal
01
Overview
The respiratory syncytial virus (RSV) neutralizing antibody is a monoclonal antibody being developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University. It is designed as a next-generation, broad-spectrum therapeutic or prophylactic agent that targets the RSV fusion (F) protein. By binding to highly conserved epitopes, likely on the pre-fusion conformation of the F protein, the antibody neutralizes the virus and prevents it from entering host cells. This candidate is currently in the preclinical stage of development and aims to provide superior potency and coverage compared to existing RSV immunotherapies, potentially offering protection against a wide range of RSV strains.
- Other names
- next-generation broad-spectrum RSV neutralizing antibodyRSV neutralizing antibodybroad-spectrum RSV neutralizing antibody
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on respiratory syncytial virus neutralizing antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus neutralizing antibody.